Sahin Ethem, Taş Ebru, Dağtekin Ergür Emine Nur, Cuhali B Deniz, Gürsel A Okan
Department of Otolaryngology, Medicine Faculty of Maltepe University, Istanbul, Turkey.
Kulak Burun Bogaz Ihtis Derg. 2008 Mar-Apr;18(2):79-84.
We evaluated three-year clinical and laboratory results of specific immunotherapy (SIT) for allergenic house dust mite species, Dermatophagoides pteronyssinus and D. farinae.
The study included 26 patients (6 males, 20 females; mean age 28 years; range 17-56 years) who had allergic rhinitis and were found to be sensitive to D. pteronyssinus and D. farinae. Due to unresponsiveness to other treatment modalities, the patients received subcutaneous SIT for three years. Symptoms (nasal stuffiness, rhinorrhea, itching, sneezing, headache, eye symptoms, and smelling) were graded before and at the end of SIT, and blood eosinophilia, total IgE and specific IgE levels were determined.
At the end of three years, the number of patients that showed strong positivity to D. pteronyssinus and D. farinae decreased from 26 (100%) to 3 (11.5%) (p=0.0001) and from 18 (69.3%) to 4 (15.4%) (p<0.005), respectively. There were significant decreases in blood eosinophilia, total IgE and specific IgE levels, and in the severity of all symptoms related to the nose, head, and eye.
Specific immunotherapy reduces symptoms in patients with allergic rhinitis. It is an effective treatment method for allergic rhinitis if performed by trained physicians in carefully selected patients.
我们评估了针对变应性屋尘螨种类（粉尘螨和屋尘螨）的特异性免疫疗法（SIT）的三年临床和实验室结果。
该研究纳入了26例患者（6例男性，20例女性；平均年龄28岁；范围17 - 56岁），这些患者患有过敏性鼻炎，且被发现对粉尘螨和屋尘螨敏感。由于对其他治疗方式无反应，这些患者接受了三年的皮下特异性免疫疗法。在特异性免疫疗法开始前和结束时对症状（鼻塞、流涕、瘙痒、打喷嚏、头痛、眼部症状和嗅觉）进行分级，并测定血液嗜酸性粒细胞、总IgE和特异性IgE水平。
三年结束时，对粉尘螨和屋尘螨显示强阳性的患者数量分别从26例（100%）降至3例（11.5%）（p = 0.0001），从18例（69.3%）降至4例（15.4%）（p < 0.005）。血液嗜酸性粒细胞、总IgE和特异性IgE水平以及与鼻、头部和眼部相关的所有症状的严重程度均有显著下降。
特异性免疫疗法可减轻过敏性鼻炎患者的症状。如果由经过培训的医生在精心挑选的患者中进行，它是一种治疗过敏性鼻炎的有效方法。
